Skip to content
value.today
PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

🇺🇸 Cranbury, New Jersey, USAPharmaceuticalsFounded 2013

Formerly PJ Pharmaceuticals, Inc.

Total raised
$74 M
1 round on record
Latest round
$74 M
Feb 2017
First round on record
Feb 2017
Today
Went public
See the company page

PMV Pharmaceuticals, Inc. is listed today as PMV Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PMV Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2017$74 MNo. 1$50 to $250 million

PMV Pharmaceuticals, Inc.: Raise no. 1, Feb 2017

Investors in this round

9 investors had bought by the notice of Mar 2, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for PMV Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$74 M of $74 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Mack · Executive Officer, Director
  • Arnold Levine · Director
  • Arnold Oronsky · Director
  • Peter Thompson · Director
  • Steve Winick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David H. Mack, Ph.D., President. Source: SEC Form D, newest notice filed Mar 2, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PMV Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2017).

    SEC Form D · Mar 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2017

That is all the official record says: PMV Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of PMV Pharmaceuticals, Inc. are on record.

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in PMV Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Boxer Asset Management Inc.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Boxer Capital, LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Euclidean Capital LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Greenland A LLCOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Greenland FP LLCOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Greenland NFP B Ltd.Companynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Greenland NFP LLCOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
InterWest Management Partners X, LLCFund or asset managernot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Interwest Partners X LPFund or asset managernot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
MVA Investors, LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Nextech V GP S.A R.L.Companynot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Nextech V Oncology S.C.S., SICAV-SIFPersonnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
OrbiMed Capital GP V LLCFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series D preferred stock (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.

Largest shareholders today

Institutions holding PMV Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PMV Pharmaceuticals, Inc.
NameRoleNamed in
David MackExecutive officerMar 2017
Arnold LevineDirectorMar 2017
Arnold OronskyDirectorMar 2017
David MackDirectorMar 2017
Peter ThompsonDirectorMar 2017
Steve WinickDirectorMar 2017

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.